Clinical Trial reference link:
NCT01650805You are here
EPIC
Ponatinib in Newly Diagnosed CML
Recruitment period:
1 June 2012 to 1 October 2013Trial period:
1 June 2012 to 1 October 2013Treatments:
For newly diagnosed patients:
noThis study has been terminated
(Study terminated based on evaluation of safety data)
Sponsor: Ariad Pharmaceuticals
Information provided by (Responsible Party): Ariad Pharmaceuticals
First received: July 18, 2012
Last updated: October 18, 2013
Last verified: October 2013
This multicenter, international,Phase 3 Randomized, Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase